Meylan, France

Evelyne Jouvin-Marche



 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2010

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Evelyne Jouvin-Marche: Innovator in Medical Research**

Introduction

Evelyne Jouvin-Marche is a notable inventor based in Meylan, France, recognized for her contributions to the field of medical research. With a focus on innovating compositions to treat pathologies associated with MSRV/HERV-W, she has made significant strides in her career.

Latest Patents

Jouvin-Marche holds a patent for a novel composition aimed at treating conditions linked to MSRV/HERV-W. The inventive composition includes a selection of antibodies, specifically anti-Env-SU MSRV/HERV-W antibodies and anti-TLR4 antibodies, which are designed to bind with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor within this fraction. This innovation is crucial in advancing therapeutic options for patients affected by this pathology.

Career Highlights

Throughout her career, Evelyne has worked with prominent organizations such as bioMérieux, Inc. and the Institut National de la Santé et de la Recherche Médicale (INSERM). Her tenure at these institutions has strengthened her expertise and allowed her to collaborate on groundbreaking research projects.

Collaborations

Evelyne Jouvin-Marche has collaborated with esteemed colleagues, including Patrice Marche and Alexandre Rolland. These collaborations have fostered a creative environment conducive to innovation in medical research and treatment development.

Conclusion

In summary, Evelyne Jouvin-Marche is an influential figure in the realm of medical inventions, particularly in the treatment of MSRV/HERV-W associated pathologies. Through her pioneering research and collaborations, she continues to make an impactful difference in her field. With her innovative spirit and dedication, the medical community looks forward to her future contributions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…